Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHA:600381)
3.410
+0.030 (0.89%)
Jul 30, 2026, 3:00 PM CST
SHA:600381 Revenue
Qinghai Spring Medicinal Resources Technology had revenue of 43.80M CNY in the quarter ending March 31, 2026, a decrease of -47.58%. This brings the company's revenue in the last twelve months to 303.67M, up 12.75% year-over-year. In the year 2025, Qinghai Spring Medicinal Resources Technology had annual revenue of 343.42M with 27.07% growth.
Revenue (ttm)
303.67M
Revenue Growth
+12.75%
P/S Ratio
6.43
Revenue / Employee
2.27M
Employees
134
Market Cap
1.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 343.42M | 73.16M | 27.07% |
| Dec 31, 2024 | 270.26M | 56.39M | 26.36% |
| Dec 31, 2023 | 213.88M | 53.70M | 33.52% |
| Dec 31, 2022 | 160.18M | 32.41M | 25.37% |
| Dec 31, 2021 | 127.76M | 3.50M | 2.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Enwei Pharmaceutical | 879.60M |
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 862.85M |
| Zhejiang Shengda Bio-Pharm | 830.53M |
| Ginwa Enterprise (Group) | 563.66M |
| Zhejiang Shapuaisi Pharmaceutical | 459.57M |
| Anhui Huangshan Capsule | 437.17M |
| Guhan Pharmaceutical Group | 344.12M |
| Shandong Sinobioway Biomedicine | 283.34M |